Yannick Kerloëguen

411 total citations
10 papers, 227 citations indexed

About

Yannick Kerloëguen is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yannick Kerloëguen has authored 10 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yannick Kerloëguen's work include Glioma Diagnosis and Treatment (8 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Brain Metastases and Treatment (3 papers). Yannick Kerloëguen is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Brain Metastases and Treatment (3 papers). Yannick Kerloëguen collaborates with scholars based in Switzerland, United States and France. Yannick Kerloëguen's co-authors include Olivier Chinot, Timothy F. Cloughesy, Gudrun Zahlmann, Lauren E. Abrey, David R. Macdonald, Wolfgang Wick, Ryo Nishikawa, Roger Henriksson, Frank Saran and Warren Mason and has published in prestigious journals such as Journal of Clinical Oncology, Neuro-Oncology and Current Neurology and Neuroscience Reports.

In The Last Decade

Yannick Kerloëguen

9 papers receiving 225 citations

Peers

Yannick Kerloëguen

GENET

PRM

RNMI

Mary Jane Lim-Fat Canada

Carlos Mesía Spain

Anja Gijtenbeek Netherlands

Claire Faulkner United Kingdom

Anna M. Tassinari United States

Maya Srikanth Graham United States

Domenico Grosso Italy

Joo Yeon Nam United States

Weiyan Shi China

Macarena I. de la Fuente United States

Mary Jane Lim-Fat Canada

Yannick Kerloëguen

171 ×1.0

GENET

101 ×1.4

PRM

73 ×1.0

RNMI

40 ×0.7

36 ×0.8

Citations per year, relative to Yannick Kerloëguen Yannick Kerloëguen (= 1×) peers Mary Jane Lim-Fat

Countries citing papers authored by Yannick Kerloëguen

Since Specialization

Citations

This map shows the geographic impact of Yannick Kerloëguen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yannick Kerloëguen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yannick Kerloëguen more than expected).

Fields of papers citing papers by Yannick Kerloëguen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yannick Kerloëguen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yannick Kerloëguen. The network helps show where Yannick Kerloëguen may publish in the future.

Co-authorship network of co-authors of Yannick Kerloëguen

This figure shows the co-authorship network connecting the top 25 collaborators of Yannick Kerloëguen. A scholar is included among the top collaborators of Yannick Kerloëguen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yannick Kerloëguen. Yannick Kerloëguen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2022). A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 18(10). 1185–1198. 26 indexed citations

Pook, David, Daniel M. Geynisman, Joan Carles, et al.. (2022). A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). 95–95. 5 indexed citations

Wick, Wolfgang, Olivier Chinot, Martin Bendszus, et al.. (2016). Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology. 18(10). 1434–1441. 68 indexed citations

Chinot, Olivier, Josep Garcia, Sylvie Romain, et al.. (2016). ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio. Neuro-Oncology. 18(suppl_6). vi5–vi5.

Chinot, Olivier, Josep Garcia, Sylvie Romain, et al.. (2016). Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.. Journal of Clinical Oncology. 34(15_suppl). 2020–2020. 2 indexed citations

Chinot, Olivier, Wolfgang Wick, Martin J. van den Bent, et al.. (2014). AT-17 * RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 16(suppl 5). v12–v12. 1 indexed citations

Wick, Wolfgang, Olivier Chinot, Warren Mason, et al.. (2014). Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).. Journal of Clinical Oncology. 32(15_suppl). 2051–2051. 5 indexed citations

Chinot, Olivier, Wolfgang Wick, Warren Mason, et al.. (2013). FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 15. 105–106. 3 indexed citations

Chinot, Olivier, David R. Macdonald, Lauren E. Abrey, et al.. (2013). Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy. Current Neurology and Neuroscience Reports. 13(5). 347–347. 94 indexed citations

10.

Wick, Wolfgang, Timothy F. Cloughesy, Ryo Nishikawa, et al.. (2013). Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 31(15_suppl). 2002–2002. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact